Inviragen Report issue

For profit Phase 1 Phase 2
Founded: Fort Collins CO United States (2005)
Status: Acquired by Takeda (2013)

Organization Overview

First Clinical Trial
2010
NCT01224639
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Inviragen Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

live tetravalent chimeric dengue vaccine (DENGVAXIA) (1 trial)

Drugs in Phase 1 Trials (2)

inv21 (1 trial)

live, attenuated, dengue serotype 1, 2, 3, 4 virus (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dengue (Phase 2)

Enterovirus Infections (Phase 1)

Fever (Phase 1)

Foot-and-Mouth Disease (Phase 1)

Hand, Foot and Mouth Disease (Phase 1)

Mouth Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3